This qualitative study investigated subjective experiences of self-stigmatization and self-destigmatization among people living with bipolar disorder (BD). We conducted in-depth interviews focusing on self-stigmatization and self-destigmatization with 22 individuals living with BD. The interview transcripts were thematically analyzed using a mixed inductive and deductive approach. Thirty-six codes were extracted and organized into six themes: language, behaviors, relationships, personal experience, identity, and healthcare. Each theme was characterized by an evolution process, and the codes were distributed in a step-by-step order as landmarks. The process begins with the experience of self-stigmatization, and develops toward self-destigmatization. This study presents a new six-dimension process called the "self-destigmatization process" (SDP), a personal and interrelational process that deconstructs self-stigmatization. Clinicians can use the landmarks of the process for clinical assessment and therapeutic interventions to increase recovery orientation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10597-020-00614-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Disclosure costs: The impact of bipolar diagnosis and social desirability on stigma.
J Affect Disord
January 2025
Department of Psychology, Auburn University, United States of America.
Background: The previous literature concerned with understanding stigma affecting patients with bipolar disorder relies predominantly on qualitative and survey approaches, and rarely contends with the potential role of social desirability on disclosure. The current project employs a 2 × 2 experimental approach to establish the presence of stigmatizing attitudes in a context with real social consequences (i.e.
View Article and Find Full Text PDFBariatric surgery and HIV: Joint venture between family, primary care, and HIV physicians.
J Family Med Prim Care
December 2024
Department of HIV and Blood Borne Viruses, Milton Keynes University Hospital, NHS Foundation Trust, Milton Keynes, UK.
We report a case of a 49-year-old female with a history of HIV infection for 12 years. The patient had excellent compliance with antiretroviral medications, raltegravir 400 mg twice daily and truvada once daily for HIV. Over the years, she maintained an undetectable viral load with a CD4+ count >200 cells/μL.
View Article and Find Full Text PDF12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study.
EClinicalMedicine
August 2024
Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, United Kingdom.
Background: While semaglutide, approved for type-2 diabetes mellitus (T2DM), is being investigated as a treatment for brain disorders, concerns over adverse neuropsychiatric events have emerged. More data are therefore needed to assess the effects of semaglutide on brain health. This study provides robust estimates of the risk of neurological and psychiatric outcomes following semaglutide use compared to three other antidiabetic medications.
View Article and Find Full Text PDFSex differences in clinically diagnosed psychiatric disorders over the lifespan: a nationwide register-based study in Sweden.
Lancet Reg Health Eur
December 2024
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Background: Limited studies exist on sex differences in incidence rates of psychiatric disorders across the lifespan. This study aims to analyze sex differences in the incidence rates of clinically diagnosed psychiatric disorders over the lifespan.
Methods: We conducted a nationwide register-based cohort study, including all individuals who were born in Sweden and lived in Sweden between 2003 and 2019, including 4,818,071 females and 4,837,829 males.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!